Acid phosphatases are enzymes capable of hydrolyzing orthophosphoric acid esters in an acid medium. Prostatic acid phosphatase has served as a tumor marker for metastatic prostate cancer for many years. We have cloned a new human acid phosphatase gene (named testicular acid phosphatase, ACPT), which is expressed mainly in testis and to a lower extent in the prostate, trachea, and other tissues. This gene maps to chromosome 19q13.4, in an area that harbors many cancer-related genes. The testicular acid phosphatase gene is composed of 11 exons, and the protein is predicted to have a luminal domain, a transmembrane domain, and a cytoplasmic domain. The N-terminal end of the protein encodes a signal peptide. The protein has approximately 50% homology with both the prostatic and the lysosomal acid phosphatases, and the position of the cysteine residues, the N-glycosylation sites, and the histidine catalytic site are conserved among the three proteins. The testicular acid phosphatase gene is up-regulated by androgens and is down-regulated by estrogens in the prostate cancer cell line LNCaP. Our preliminary results indicate that this gene exhibits a lower level of expression in testicular cancer tissues than in their normal counterparts.
INTRODUCTION
Acid phosphatases (ACPs; orthophosphoric monoester phosphohydrolases) are a group of enzymes capable of hydrolyzing esters of orthophosphoric acid in an acid medium (Romas et al., 1979) . Four true isoenzymes (that is, forms with differences originating at the structural level of the gene) have been identified: erythrocytic, lysosomal, prostatic, and macrophagic acid phosphatases (Moss et al., 1995) . The different forms are often associated with particular characteristics that may not necessarily be absolute or specific. Erythroid acid phosphatase (ACP1) 2 is a small molecule that belongs to the group of acid phosphatases that are not inhibited by tartrate. The gene is 18 kb in length, consists of 7 exons (Bryson et al., 1995) , and has been mapped to the short arm of chromosome 2 (Ferguson-Smith et al., 1973) . The human lysosomal acid phosphatase gene (ACP2) was cloned by Pohlmann et al. (1988) and was assigned to chromosome 11. ACP2 is about 9 kb in size and is composed of 11 exons. The luminal domain is encoded by exons 2 to 10; exon 1 encodes the signal sequence and the first 8 amino acids, while exon 11 encodes the transmembrane and cytoplasmic domains (Geier et al., 1989; Pohlmann et al., 1988) . Human prostatic acid phosphatase was the first urological tumor marker. It has been used for over 50 years for the diagnosis and prognosis of prostate cancer (Sharief and Li, 1994; Vihko et al., 1988) . This marker has now been largely replaced by prostatespecific antigen (PSA), which is a more sensitive and specific biomarker for the diagnosis and monitoring of prostatic carcinoma (Diamandis, 1998) . Human prostatic acid phosphatase (ACPP or ACP3) is formed of 10 exons, spanning an area of approximately 40 kb on chromosome 3 (Sharief et al., 1989; Li, 1992, 1994; Vihko et al., 1988; Yeh et al., 1987) . The gene encoding human macrophage acid phosphatase has been cloned and mapped to chromosome 19p13.2-p13.3 (Cassady et al., 1993; Ketcham et al., 1989; Lord et al., 1990) , has an open reading frame of 975 bp, and is resistant to inhibition by tartarate.
The chromosomal band 19q13.3-q13.4 is nonrandomly rearranged in a variety of solid tumors and harbors malignancy-related genes, including the RRAS oncogene and the apoptosis regulator gene BAX (Apte Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under Accession No. AF321918. 1 To whom correspondence and reprint requests should be addressed at Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. Telephone: (416) 586-8628. E-mail: ediamandis@mtsinai.on.ca. et al., 1995) . In our previous work, we cloned and mapped a number of kallikrein genes located in this region, including PSA and other genes that were found to be differentially expressed in a variety of tumors, including prostate cancer (Diamandis et al., 2000; Yousef et al., , 2000a . Here, we describe the cloning of a new gene, the testicular acid phosphatase gene, which is highly homologous to prostatic and lysosomal acid phosphatases. Our preliminary data indicate that this gene is regulated by steroid hormones and that its expression is significantly lower in testicular cancer tissues than in normal testicular tissues.
MATERIALS AND METHODS
Cloning of the testicular acid phosphatase gene. Sequencing information around the chromosomal region 19q13.4 and bacterial artificial chromosome (BAC) localization maps were obtained from the Lawrence Livermore National Laboratory (LLNL). Using different gene prediction programs, a putative new gene was identified in this region. The BAC clone that contains this gene (BC 781134) was obtained from the LLNL. This clone was digested, blotted on a membrane, and hybridized with gene-specific probes for the putative testicular acid phosphatase gene. Probes were synthesized according to the predicted sequence of the new gene, and positive fragments were subcloned and sequenced to verify the structure of the putative gene.
Expressed sequence tag (EST) searching. The predicted exons of the putative new gene were subjected to homology search using the BLASTN algorithm (Altschul et al., 1997) on the National Center for Biotechnology Information Web server (http://www ncbi.nlm.nih.gov/ BLAST/) against the human EST database (dbEST). Five clones with Ͼ97% identity were obtained from the IMAGE Consortium (Lennon et al., 1996) through Research Genetics Inc. (Huntsville, AL) ( Table  1) . The clones were propagated, purified, and sequenced from both directions with an automated sequencer, using insert-flanking vector primers.
Rapid amplification of cDNA ends (5Ј RACE).
According to the EST sequence data and the predicted structure of the gene, two gene-specific primers were designed (RN, 5Ј CTC CAG GGC CTC CTG GTA CT 3Ј; and RN2, 5Ј GGA ATA CCT GGG GAC AGG AC 3Ј). Two rounds of RACE reactions (nested polymerase chain reaction (PCR)) were performed with 5 l Marathon Ready cDNA from human testis (Clontech, Palo Alto, CA) as a template. The reaction mix and PCR conditions were in accordance with the manufacturer's recommendations.
Tissue expression. Total RNA isolated from 25 different human tissues was purchased from Clontech. We prepared cDNA as described below and used it for PCRs. Tissue cDNAs were amplified at various dilutions. To exclude nonspecific amplification, the PCR products were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The inserts were then sequenced from both directions using vector-specific primers, with an automated DNA sequencer.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total RNA was extracted from normal and malignant tissues using Trizol reagent (Gibco BRL, Gaithersburg, MD) following the manufacturer's instructions. The RNA concentration was determined spectrophotometrically. Two micrograms of total RNA was reverse-transcribed into first-strand cDNA using the Superscript preamplification system (Gibco BRL). The final volume was 20 l. Two gene-specific primers were designed (F1MD, 5Ј ATGGCCGGC-CTGGGGTTTTG 3Ј; and R6PD, 5Ј ACATGTTGGGGTCCAGTGTCA 3Ј), and PCR was carried out in a reaction mixture containing 1 l of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 M dNTPs (deoxynucleoside triphosphates), 150 ng of primers, and 2.5 units of HotStar DNA polymerase (Qiagen Inc., Valencia, CA) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 94°C for 15 min to activate the polymerase, followed by 45 cycles of 94°C for 30 s, 64°C for 30 s, and 72°for 1 min, and a final extension step at 72°C for 10 min. Another pair of primers (F1PD, 5Ј CAGTCT-GACCAACACGCAAG 3Ј, and R6PD, 5Ј ACATGTTGGGGTCCAGT-GTCA 3Ј) was used for tissue expression and tumor screening. Equal amounts of PCR products were electrophoresed on 1.5% agarose gels and visualized by ethidium bromide staining. All primers for RT-PCR spanned at least two exons to avoid contamination by genomic DNA.
Prostate cancer cell line and hormonal stimulation experiments.
The LNCaP prostate cancer cell line was purchased from the American Type Culture Collection (ATCC; Rockville, MD). Cells were cultured in RPMI medium (Gibco BRL) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%), antibiotics, and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. Twenty-four hours before the experiments, the culture medium was changed into phenol red-free medium containing 10% charcoal-stripped fetal bovine serum. For stimulation experiments, various steroid hormones dissolved in 100% ethanol were added to the culture medium at a final concentration of 10 Ϫ8 M. Cells stimulated with 100% ethanol were included as controls. The cells were cultured for 24 h and then harvested for mRNA extraction.
Testicular cancer tissue specimens. Normal and cancerous testicular tissue samples were obtained from 14 patients who had undergone radical orchiectomy for testicular tumors at the Charite University Hospital, Berlin, Germany. Six tumors were seminomas, and 8 tumors were nonseminomas. The patients did not receive any hormonal therapy before surgery. The use of these tissues for research purposes was approved by the Ethics Committee of the Charite Hospital. Fresh testicular tissue samples were obtained from the cancerous and noncancerous parts of the same testis that had been removed. Small pieces of tissue were dissected immediately after removal of the testis and stored in liquid nitrogen until analysis. Histological analysis from all the tissue pieces was performed as previously described (Meyer et al., 1997) , to ensure that the tissue was either malignant or benign. The tissues were pulverized with a hammer under liquid nitrogen, and RNA was extracted using RNeasy minispin columns (Qiagen) following the manufacturer's instructions.
RESULTS

Cloning and Characterization of the Testicular Acid Phosphatase Gene
The BAC clone (BC 781134) was obtained from the LLNL, purified, digested, and probed with a testicular acid phosphatase-specific oligonucleotide probe. Positive fragments were sequenced, to obtain the genomic structure of the gene. EST database search, PCR using exon-specific primers derived from the predicted exons of the gene, 5Ј RACE, and protein and domain homology search were used to identify the full structure of the testicular acid phosphatase gene.
The testicular acid phosphatase gene (official gene symbol ACPT, approved by the Human Gene Nomenclature Committee) is composed of 11 coding exons and 10 intervening introns and spans 5 kb of genomic nucleotide sequence (Fig. 1) . All exon-intron boundaries comply with the GT/AG rule and are in good agreement with the consensus sequence of splice junctions (Breathnach and Chambon, 1981) . The cDNA of the gene consists of 1281 bp, encoding a polypeptide chain of 426 amino acids with a predicted molecular mass of 46.1 kDa. The methionine translation initiation codon is located in the first exon, and, as is the case with most vertebrate mRNAs, the start codon is surrounded by a purine in position Ϫ3 and a (G) in position ϩ4 (Kozak, 1991) . No more sequence was obtained upstream of the start codon by 5Ј RACE. Thus, the transcription initiation site is expected to be close to the translation start codon. The two most homologous genes, ACPP and ACP2, have short 5Ј untranslated regions of 23 (Vihko et al., 1988) and 9 nucleotides (Geier et al., 1989) , respectively. The coding region is followed by 61 bases of 3Ј untranslated sequence before the poly(A) tail. All exons end with an intron phase of 0 except exons 7 and 10 which have an intron phase of I, and exon 9, which has an intron phase of II. A comparison of intron phases and other characteristics of ACPT, ACP2, and ACPP is shown in Table 2 . At the protein level, testicular acid phosphatase shows 48% identity and 63% similarity with the human lysosomal acid phosphatase and 44% identity and 60% similarity with the prostatic acid phosphatase. No significant homology was found with erythroid or type 5 acid phosphatases. The amino acid sequence of the gene starts with a putative signal peptide of 28 amino acids (Fig. 2) . This signal peptide has the structural features characteristic of a signal peptide (Nielsen et al., 1997; Nielsen and Krogh, 1998) : (1) a basic N-terminal region, a central hydrophobic region, and a more polar C-terminal region; (2) alanine is present at position Ϫ3; and (3) leucine is present at positions Ϫ7 to Ϫ13 with the exception of position Ϫ8 (Fig. 3) .
The Prediction of Transmembrane Helices in Proteins program (Sonnhammer et al., 1998) predicted that amino acids 1-390 represent a luminal (extracellular) domain, amino acids 391-413 represent a transmembrane domain, and amino acids 414 -425 represent a cytoplasmic domain (Fig. 4) . The same results were obtained by the TMpred program (Hofmann and Stoffel, 1993 ) (data not shown).
Scanning of the testicular acid phosphatase protein against the PROSITE database of protein families and domains (Hofmann et al., 1999) revealed the presence of four potential N-glycosylation sites, a phosphohistidine signature domain, and a histidine acid phosphatase active site signature (Table 3) . Screening of the CD (conserved domain) database at the National Center for Biotechnology Information (NCBI) revealed the presence of the same domains.
To study the phylogenetic relatedness of the new testicular acid phosphatase, we aligned its amino acid sequence with all known acid phosphatases, human alkaline phosphatase, and some known lysosomal enzymes using the Clustal X multiple alignment pro- gram. Distance matrix and parsimony trees were constructed using the neighbor-joining/UPGMA and Protpars parsimony methods. All possible trees grouped testicular acid phosphatase together with both ACPP and ACP2 in one group (Fig. 5) .
Tissue Expression and Hormonal Regulation of the Testicular Acid Phosphatase Gene
We screened cDNA from 25 normal human tissues by PCR using gene-specific primers. The gene is expressed at highest levels in the testis. Lower levels of expression are found in the trachea, prostate, bone marrow, spinal cord, colon, fetal brain, heart, thymus, fetal liver, spleen, pancreas, and skeletal muscle (Fig. 6) . To verify the RT-PCR specificity, the PCR products were cloned and sequenced. The multiple bands in some tissues represent splice variants, as exemplified in detail below. Figure 7 shows that the testicular acid phosphatase gene is under steroid hormone regulation in the prostatic carcinoma cell line LNCaP. Expression of the gene, at the mRNA level, is up-regulated by mibolerone (a synthetic androgen) and dihydrotestosterone (DHT) and is down-regulated by estrogen (estradiol) and progestin (norgestrel).
Testicular Acid Phosphatase Gene Expression in Testicular Tumors
To investigate the possible differential expression of the testicular acid phosphatase gene in testicular tumors, we studied 14 pairs of matched cancerous/normal tissues of testicular tumors, including 6 seminomas and 8 nonseminomas (teratoma, embryonal carcinoma, and choriocarcinoma). cDNAs from these tissues were examined by PCR using gene-specific primers. The testicular acid phosphatase gene was found to be abundantly expressed in all 14 normal testicular tissues. Expression was very low or undetectable in 10 of the 14 cancerous counterparts, lower than normal in 2 tumors, and comparable to normal in
FIG. 2.
Multiple alignment of the amino acid sequences of testicular acid phosphatase (ACPT), prostatic acid phosphatase (ACPP), and lysosomal acid phosphatase (ACP2) proteins. Numbers of the amino acid residues of each protein are shown on the left of each row. Identical residues are highlighted in black, and similar residues are highlighted in gray. The amino acid residues of the signal peptides are shown in italics. The positions of the conserved cysteine residues are marked by asterisks. N-glycosylation sites are double underlined, and transmembrane domains are boxed. The histidine residues important for catalytic activity are shown by an arrow.
another 2 tumors (Fig. 8) . Actin, a housekeeping gene, was used as a control, and approximately the same level of expression for the latter was found in all normal and malignant tissues, indicating that the lower level of testicular acid phosphatase expression was not due to mRNA variation between samples.
Splice Variants of the Testicular Acid Phosphatase Gene
PCR screening using gene-specific primers (F1MD and R6PD) revealed the presence of up to three closely spaced bands in some of the tissue cDNAs (Fig. 6) . These bands were digested by two different restriction enzymes (to allow better separation), gel-purified, cloned, and sequenced. The middle band represents the regular form of the gene, the upper band represents splice variant 1, and the lower band represents splice variant 2 (Fig. 9) . Another short splice variant was identified in the bone marrow (splice variant 3) (data not shown). Splice variant 1 is present in the testis, trachea, prostate, and bone marrow. In this variant, the first intron is not spliced out; thus, exons 1 and 2
FIG. 3. (A) Plot of hydrophobicity and hydrophilicity of the testicular acid phosphatase (ACPT) and lysosomal acid phosphatase (ACP2).
(B) Plot illustrating the different structural regions of the signal peptide of testicular acid phosphatase. N, basic N-terminal region; H, central hydrophobic region; P, polar C-terminal region; C, cleavage site (P 2 E). Prediction of the signal peptide was performed using the SignalP server (Nielsen and Krogh, 1998). and the intervening intron are all parts of the first exon. This leads to frameshifting. The mRNA is predicted to encode a truncated protein of 92 amino acids. Splice variant 2 has the same structure as variant 1, in addition to a deleted exon 7. Splice variant 3 is similar to the regular form but is missing exons 4 and 5 and the last part of exon 3. This variant is predicted to encode a polypeptide chain of 333 amino acids.
Chromosomal Localization of the Testicular Acid
Phosphatase Gene PCR screening of the BAC clone (BC 781134) was performed using gene-specific primers for the testicular acid phosphatase gene and each of the 15 kallikrein genes that were recently cloned in this region (Diamandis et al., 2000; Yousef et al., 2000b) . The clone was positive for KLK15, KLK1, and testicular acid phosphatase, but negative for KLK3 (PSA) and other kallikreins. We have recently constructed a detailed map of the human kallikrein gene locus (Yousef et al., 2000b) . We obtained contigs of different lengths from the BAC clone (BC781134), and by using long-PCR strategies, we were able to construct a larger contig that contains the testicular acid phosphatase gene, as well as the KLK1 and KLK15 genes. Sequence analysis indicated that the testicular acid phosphatase gene is the most centromeric and is transcribed from centromere to telomere. The KLK1 and the KLK15 genes are transcribed in the opposite direction. The KLK3 gene (coding for prostate-specific antigen) is the most telomeric and is transcribed in the same direction as the testicular acid phosphatase gene. A detailed map of the region, showing distances between these four genes and BAC clones, is shown in Fig. 10 . No other genes were found to map between the ACPT and the KLK1 genes.
FIG. 4.
A plot illustrating the predicted domains of testicular acid phosphatase using the TMHMM server. The signal peptide and extracellular, transmembrane, and intracellular domains are shown. For more details, see Results. a Amino acid position according to GenBank Accession No. AF321918 and Fig. 1.   FIG. 5 . Phylogenetic tree using the protein parsimony algorithm. All known human acid phosphatases were included in the analysis, in addition to human alkaline phosphatase and some lysosomal enzymes. The testicular acid phosphatase enzyme was aligned with both the ACPP and the ACP2 genes in one group, indicating that these genes arose from a common ancestral gene (see Discussion for details). Proteins included are as follows (the GenBank accession numbers are shown in parentheses): erythroid acid phosphatases A and B (NM_004300 and NM_007099), human lysosomal acid phosphatase (NP_001601), human prostatic acid phosphatase (NP_001090), ACP5 (tartrate-resistant acid phosphatase) (NP_001602), human alkaline phosphatase (NP_000469), alpha glucosidase (NP_004659), cathepsin D (NM_001909), and testicular acid phosphatase (AF321918).
DISCUSSION
Acid phosphatase (EC 3.1.3.2) is represented by a number of enzymes that can be differentiated according to structural, catalytic, and immunological properties (Waheed et al., 1985) . The structural features of the newly identified testicular acid phosphatase gene are quite similar to those of the prostatic and lysosomal acid phosphatases at both the DNA and the protein levels. At the genomic level, the following structural features are conserved in all three genes: (a) the numbers of exons are similar (except for the lack of exon 11, which contains the transmembrane domain, in prostatic acid phosphatase); (b) the lengths of all exons are comparable or identical (except for exon 11 of ACP2); (c) the intron phases are conserved in all three genes (except for exon 7 in ACPP); and (d) all exon-intron boundaries follow the GT/AG rule (except for exon 3 in ACPP). Table 2 summarizes various structural features of the three genes.
At the protein level, multiple alignment of testicular acid phosphatase with the prostatic and lysosomal acid phosphatases (Fig. 2) indicates the presence of a high degree of homology (ϳ50%) and the existence of many conserved domains. Furthermore, the positions of six cysteine residues are completely conserved in all three proteins (Fig. 2) . Transmembrane prediction programs indicated that the testicular acid phosphatase protein contains a short cytoplasmic domain, a transmembrane domain, and a long luminal (extracellular) domain (Fig. 4) . This pattern is quite similar to that of the human, rat, and mouse lysosomal acid phosphatases, and the positions of these three domains are nearly identical (Geier et al., 1991) . As is the case with ACPP, the testicular acid phosphatase gene was found to be up-regulated by androgens and down-regulated by estrogen (Fig. 7) . In addition, phylogenetic analysis indicated that ACPT is more closely related to ACPP and ACP2 proteins and to a lesser degree to other acid phosphatases (Fig. 5) . Although experimental evidence is lacking, the newly identified gene should be considered to encode an acid phosphatase, based on structural features and protein similarities. These data also suggest that these three enzymes (testicular, prostatic, and lysosomal acid phosphatases) belong to a multigene family that likely originated from an ancestral gene during the course of evolution. It has been suggested that the ancestral exon 11 was lost in the ACPP gene by deletion, or alternatively, this exon could have been added after gene duplication (Sharief et al., 1989; Sharief and Li, 1992) .
A number of acid phosphatases, from both prokaryotes and eukaryotes, share two regions of sequence similarity, each centered around a conserved histidine residue. These two histidines seem to be involved in the enzymes' catalytic mechanism (Ostanin et al., 1992; Van Etten et al., 1991) . The first histidine is located close to the N-terminal end, while the second is located in the C-terminal part of the enzyme (Table 3) . Enzymes belonging to this family are called "histidine acid phosphatases" and include all mammalian lysosomal and prostatic acid phosphatases. These two histidines and their surrounding conserved sequences are present in the testicular acid phosphatase protein (Table 3 and Fig. 2) . Furthermore, the predicted N-glycosylation sites match well with the corresponding sites for glycosylation of lysosomal and prostatic acid phosphatases (Table 3 and Fig. 2 ). These data provide further evidence that the new gene belongs to the acid phosphatase family.
The presence of alternatively spliced forms is not uncommon among acid phosphatases. Alternative splicing of exons 3 and 4 was shown to account for two different isoenzymes of ACP1 (Bryson et al., 1995; Wo et al., 1992) , and a rare variant of ACP1, called ACP1*KUK, was identified in Czechoslovakia (Arnaud et al., 1989 (Arnaud et al., , 1992 The 3Ј untranslated region of the testicular acid phosphatase gene is relatively short in comparison to the human lysosomal and ACPP genes.
The length of the signal peptide (28 amino acids) is comparable to that of prostatic and lysosomal acid phosphatases (32 and 30 amino acids, respectively), and the predicted cleavage site occurs at a similar position in all three genes (Fig. 2) .
The testicular acid phosphatase gene is up-regulated by androgens and is down-regulated by estrogens in the LNCaP prostate cancer cell line. The two available tumor markers for prostate cancer, PSA and ACPP, were also shown to be up-regulated by androgens in prostate cells (Diamandis, 1998; Moss et al., 1995; Romas et al., 1979; Yam et al., 1980) . Testicular cancer is the most common malignancy in men ages 15-34 years, and its incidence has increased over the past 35 years (Hayes et al., 1990; Parker, 1997) . Testicular germ cell neoplasms originate from germ cells and proceed through a premalignant carcinoma in situ (CIS) stage. Time for progression from CIS to invasive tumor is roughly 5-7 years (Lutzker and Barnard, 1998) . Testicular germ cell tumors exhibit nonrandom loss of DNA sequences scattered among several distinct chromosomal arms (Sandberg et al., 1996) , suggesting that the loss of tumor suppressor genes contributes to progression from CIS. In close proximity to ACPT, there are three genes that have been implicated in carcinogenesis, RRAS, BAX, and a newly identified homologue of Bcl-2 (Scorilas et al., in press ). However, we do not have any data showing either gain or loss of genetic material affecting these genes in cancer. A unique feature of testicular tumors is that they are "curable"; i.e., they are extremely sensitive to chemotherapy (Lutzker and Barnard, 1998) , and early diagnosis of the disease by a reliable tumor marker is of extreme importance. The possible role of testicular acid phosphatase as a testicular biomarker or as a therapeutic target needs further experimentation.
Testicular cancer is one of the hormonally related cancers (Henderson and Feigelson, 2000) . The role of steroid hormones in the development of testicular cancer is not clear, but two recent reports suggest that one possible cause of testicular cancer may be suboptimal androgen levels (James, 2000) and environmental estrogen exposure (Parker, 1997) . One possible mechanism of action of these hormones is through altering the expression of hormonally regulated genes. Testicular acid phosphatase is one potential candidate gene.
In conclusion, we cloned a new acid phosphatase gene that is expressed mainly in testis and has a high degree of homology and structural similarity to prostatic and lysosomal acid phosphatases. This new gene is under steroid hormonal regulation, and its expression is low in testicular cancer tissues. The clinical applicability of this gene for diagnosis, prognosis, monitoring and therapy of testicular cancer should be worth examining in future studies.
FIG. 8.
Expression of the testicular acid phosphatase gene in 14 pairs of normal and cancerous testicular tissues, as determined by RT-PCR. The gene transcript was found to be abundant in all 14 normal testicular tissues, very low or undetectable in 10 the 14 cancerous counterparts, lower than normal in 2 tumors, and comparable to normal in another 2 tumors. Actin, a housekeeping gene, was used as a control to ensure quality and equal quantity of added cDNAs. -ve, negative control. 
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